Zydus Life rises on USFDA nod for heart failure drug 0 10.07.2024 13:06 Business Standard Zydus Lifesciences gained 1.81% to Rs 1187.15 after the company announced that it has received a final approval from the United States Food and Drug Administration (USFDA) to market Sacubitril and Valsartan tablets. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
